Soluble Fas antigen in the serum of patients with colon cancer.
Serum concentration of soluble Fas antigen (sFas) was measured in 60 normal subjects and 33 patients with colon cancer. The incidence of sFas detection and its serum content were higher in patients with colon cancer compared to normal subjects. No relationships between the incidence and level of sFas and patient's sex, age, duration and stage of the disease were found. Serum content of sFas tended to increase in patients with metastases to regional lymph nodes, liver, and lungs. The role of sFas as a marker predicting clinical course and outcome of colon cancer is discussed.
Kushlinskii
N E
NE
N. N. Blokhin Cancer Research Center, Russian Academy of Medical Sciences, Moscow.
Britvin
T A
TA
Abbasova
S G
SG
Perevoshchikov
A G
AG
Prorokov
V V
VV
Kostanyan
I A
IA
Knysh
V I
VI
Lipkin
V M
VM
D000230:Adenocarcinoma / Q000097:blood* / Q000276:immunology / Q000532:radiotherapy; D000328:Adult; D000367:Age Factors; D000368:Aged; D003110:Colonic Neoplasms / Q000097:blood* / Q000276:immunology / Q000532:radiotherapy; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000097:blood / Q000532:radiotherapy / Q000556:secondary; D008297:Male; D008875:Middle Aged; D012737:Sex Factors; D012995:Solubility; D019014:fas Receptor / Q000097:blood*
D019014:fas Receptor